Cargando…
Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions
Carcinoembryonic antigen (CEA), carbohydrate antigens 15–3, 19–9 and 72–4 (CA 15–3, CA 19–9 and CA 72–4), cytokeratin 19 fragments (CYFRA 21–1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a sp...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362942/ https://www.ncbi.nlm.nih.gov/pubmed/10576665 http://dx.doi.org/10.1038/sj.bjc.6690807 |
_version_ | 1782153579693342720 |
---|---|
author | Miédougé, M Rouzaud, P Salama, G Pujazon, M-C Vincent, C Mauduyt, M-A Reyre, J Carles, P Serre, G |
author_facet | Miédougé, M Rouzaud, P Salama, G Pujazon, M-C Vincent, C Mauduyt, M-A Reyre, J Carles, P Serre, G |
author_sort | Miédougé, M |
collection | PubMed |
description | Carcinoembryonic antigen (CEA), carbohydrate antigens 15–3, 19–9 and 72–4 (CA 15–3, CA 19–9 and CA 72–4), cytokeratin 19 fragments (CYFRA 21–1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15–3 and CA 72–4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15–3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of non-lymphomatous malignant effusions was CEA + CA 15–3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15–3, CYFRA 21–1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions. © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2362942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23629422009-09-10 Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions Miédougé, M Rouzaud, P Salama, G Pujazon, M-C Vincent, C Mauduyt, M-A Reyre, J Carles, P Serre, G Br J Cancer Regular Article Carcinoembryonic antigen (CEA), carbohydrate antigens 15–3, 19–9 and 72–4 (CA 15–3, CA 19–9 and CA 72–4), cytokeratin 19 fragments (CYFRA 21–1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15–3 and CA 72–4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15–3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of non-lymphomatous malignant effusions was CEA + CA 15–3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15–3, CYFRA 21–1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions. © 1999 Cancer Research Campaign Nature Publishing Group 1999-11 /pmc/articles/PMC2362942/ /pubmed/10576665 http://dx.doi.org/10.1038/sj.bjc.6690807 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Miédougé, M Rouzaud, P Salama, G Pujazon, M-C Vincent, C Mauduyt, M-A Reyre, J Carles, P Serre, G Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions |
title | Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions |
title_full | Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions |
title_fullStr | Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions |
title_full_unstemmed | Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions |
title_short | Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions |
title_sort | evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362942/ https://www.ncbi.nlm.nih.gov/pubmed/10576665 http://dx.doi.org/10.1038/sj.bjc.6690807 |
work_keys_str_mv | AT miedougem evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT rouzaudp evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT salamag evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT pujazonmc evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT vincentc evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT mauduytma evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT reyrej evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT carlesp evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions AT serreg evaluationofseventumourmarkersinpleuralfluidforthediagnosisofmalignanteffusions |